Scarica l'app Stockscreener
55.41
0.75%
0.41
Dopo l'orario di chiusura:
55.49
0.08
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
Cantor Fitzgerald Has Weak Estimate for CRSP FY2025 Earnings - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Blair William & Co. IL Has $2.32 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cetera Investment Advisers Has $1.97 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - TipRanks
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial - The Globe and Mail
Royal Bank Of Canada Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG! - TipRanks
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
Crispr Therapeutics price target raised to $12 from $10 at Barclays - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Posts Quarterly Earnings Results - MarketBeat
CRSP Stock Analysis: What’s Going on with Crispr Therapeutics AG? - Markets.com
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating - TipRanks
Brookline Capital Management Estimates CRSP Q3 Earnings - MarketBeat
Research Analysts Set Expectations for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics stock price target raised to $80 by H.C. Wainwright - Investing.com Nigeria
Banque Cantonale Vaudoise Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Earnings: Casgevy Launch Gains Momentum; Early-Stage Pipeline Progresses; Shares Undervalued - Morningstar
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption - MSN
CRISPR Therapeutics Shares Drop 6.71% on Q2 Losses and $96M Charge as $250M Volume Ranks 475th - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownHere's Why - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - The Motley Fool
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Plunges 9.63% Ahead of Q2 Earnings - AInvest
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating - TipRanks
Bayforest Capital Ltd Purchases Shares of 12,424 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
Crispr Therapeutics shares tumble after significant earnings miss By Investing.com - Investing.com Nigeria
Crispr Therapeutics shares tumble after significant earnings miss - Investing.com
Crispr Therapeutics earnings missed by $1.00, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG SEC 10-Q Report - TradingView
CRISPR Therapeutics Q2 revenue misses estimates, net loss widens - MarketScreener
CRISPR Therapeutics Reports Momentum in CASGEVY® Rollout and Clinical Trials Progress with Strong Financial Position - Quiver Quantitative
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Published on: 2025-08-04 01:34:11 - Jammu Links News
What analysts say about CRISPR Therapeutics AG stockCapitalize on market trends with confidence - Jammu Links News
1.02%
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):